Cancers and other Neoplasms

NCBiotech Company Directory is a comprehensive listing of North Carolina's life science industry New search

Company Title Company Description City
Accord Healthcare Inc.

Accord Healthcare develops and manufactures generic pharmaceuticals. Their portfolio includes therapeutics in oncology, cardiology, neurology, nephrology, urology, psychiatry, diabetes and pain management. The North Carolina location is a sales office.

Durham
AccuBeing LLC

AccuBeing creates three-dimensional cancer organoids from patients' cancer cells, which are used to test novel drug therapies, transcriptomic and epigenetic analyses. Results are used to match the patient with personalized clinical trials.

Raleigh
AccuGenomics Inc.

AccuGenomics develops gene expression tests to diagnose and monitor cancer treatment. Its technologies include Standardized Nucleic Acid Quantification (SNAQ) for quantitative PCR and Standardized RNA Sequencing (STARSEQ) for NGS platform analysis.

Wilmington
Advanced Chemotherapy Technologies Inc.

Advanced Chemotherapy Technologies, a UNC startup, has developed a novel device for infusing chemotherapies directly into poorly-vascularized pancreatic tumors.

Raleigh
Alderon BioSciences Inc.

Alderon Biosciences develops point-of-care diagnostics.

Beaufort
AlphaVax Inc.

AlphaVax develops vaccine technology with applications in infectious disease, cancer and biodefense threats.

Research Triangle Park
AnelleO

AnelleO is developing a 3D printed intravaginal ring that can be used as a platform for treating a wide range of women's health conditions.

Chapel Hill
Apeirolux Pharmaceutical Inc.

Apeirolux Pharmaceutical is developing a tumor-cell selective topical skin cream for the treatment of skin cancer.

Fuquay Varina
Array BioPharma Inc.

Array BioPharma discovers, develops and commercializes targeted, small-molecule drugs to treat cancer.

Morrisville
Arrevus Inc.

Arrevus is developing novel therapeutics for unmet medical needs in areas with high treatment failure rates, including infectious disease, brain cancer and breast cancer.

Raleigh
ATOM Inc.

ATOM Inc. provides oncology product and technology marketing and business development services, with a focus on identifying and addressing barriers to patient access.

Raleigh
Atrium Health Division of Therapeutic Research and Development

The Division of Therapeutic Research and Development at Atrium Health conducts clinical studies, patient-focused translational research and outcomes research.

Charlotte
Attagene Inc.

Attagene has developed a pathway profiling technology to evaluate the impact of pharmaceuticals and environmental chemicals on over 100 transcription factors and 48 nuclear receptors.

Morrisville
Bavarian Nordic Inc.

Bavarian Nordic develops, manufactures and commercializes cancer immunotherapies and vaccines for infectious diseases.

Morrisville
BD Diagnostics (Durham)

BD Diagnostics develops and commercializes molecular diagnostic products for various cancers, including cervical, breast, ovarian and prostate.

Durham
BD Diagnostics (Mebane)

BD Diagnostics develops and commercializes molecular diagnostic products for women's health and various cancers.

Mebane
BioCytics Inc.

BioCytics researches and develops personalized cellular immunotherapy cancer therapies with the latest technology and equipment. BioCytics also offers contract R&D, and is incubated within the Carolina BioOncology Institute.

Huntersville
Biofluidica Inc.

Biofluidica is developing novel instrumentation for the isolation and analysis of circulating biomarkers, including circulating tumor cells, in cancer patients.

Research Triangle Park
BioMarck Pharmaceuticals Ltd.

BioMarck develops drugs to treat pulmonary diseases and disorders, such as chronic obstructive pulmonary disease, ARDS, cystic fibrosis and lung cancer.

Durham
BioZyme Inc.

BioZyme develops and sells substrates for metalloproteinases (MMPs and ADAMs) which can be used in enzyme assays and other diagnostic tests.

Apex
Blue Ridge Institute for Medical Research

Blue Ridge Institute for Medical Research (BRIMR) researches small-molecule inhibitors of protein kinases and targeted cancer therapies.

Horse Shoe
bluebird bio Inc.

bluebird bio develops gene therapies and cancer immunotherapies for the treatment of genetic diseases and cancer. At its Durham site, bluebird produces lentiviral vectors for the company's gene and cell therapies.

Durham
Cancer Advances Inc.

Cancer Advances, a subsidiary of Cato Bioventures, develops immunomodulator therapeutics to treat gastrointestinal cancers.

Durham
Cancer Genetics Inc.

Cancer Genetics offers diagnostic products and services that enable precision medicine in the field of oncology. This site performs clinical pharmacogenomic testing and provides biorepository services under federally-designated clinical lab standards.

Morrisville
Carolina BioOncology Institute

CBI runs a phase I immunotherapy and personalized cancer clinical trial program, and serves as an incubator for BioCytics, its research and application program.

Huntersville
Cellective BioTherapy Inc.

Cellective BioTherapy is developing cellular and monoclonal antibody-based platforms for treating cancers, autoimmunity and immunodeficiency.

Research Triangle Park
CellSolutions LLC

CellSolutions develops liquid-based preparation and evaluation systems for cytology applications. The company's primary area of focus is women's health, including cervical cancer screening, precancer detection and evaluation of infectious disease.

Greensboro
Cereius Inc.

Cereius is developing novel radio-labeled therapeutics for treating solid tumor brain metastasis.

Durham
Charles River Laboratories (Morrisville)

Charles River Laboratories' Oncology Center of Excellence provides in vivo and in vitro oncology and immuno-oncology research services.

Morrisville
ChemQ Bioscience LLC

ChemQ Bioscience develops and markets novel liquid products, such as bio-preservation media, tissue perfusion solutions and liquid-based cytology processing kits.

Research Triangle Park
CivaTech Oncology Inc.

CivaTech Oncology has developed targeted implantable radiation devices to treat many cancer types. Products provide a targeted, customized radiation dose during a surgical resection procedure or in outpatient therapies to treat cancers.

Durham
Clavé Biodesign Inc.

Clavé Biodesign develops cell-specific peptides which can be used for therapeutic purposes related to cancer, cardiovascular disease and ophthalmology as well as for diagnostic imaging and biomarkers.

Cary
Clinipace Worldwide Inc.

Clinipace provides clinical research services to pharmaceutical, biotechnology, and medical device companies globally, working across all major therapeutic areas including oncology, gastroenterology, and nephrology and urology.

Morrisville
Cloud Pharmaceuticals Inc.

Cloud Pharmaceuticals designs and develops novel drug molecules using computational design for a wide range of therapeutic areas including cancer, inflammation, CNS disorders and rare diseases.

Research Triangle Park
Eisai Inc.

Eisai discovers, develops and markets pharmaceuticals in neurology and oncology-critical care. This site supports global partnerships, quality assurance and supply chain for the company.

Raleigh
ENVIGEN Pharmaceuticals Inc.

ENVIGEN develops classes of small drug-like molecules to treat life-threatening diseases including cancer, HIV/AIDS and neurological disorders.

Raleigh
EpiZyme Inc.

Epizyme discovers, develops and plans to commercialize innovative personalized therapeutics for patients with genetically defined cancers.

Morrisville
Eydis Bio Inc.

Eydis Bio is developing a platform of tethered molecules that enable detection and ablation of malignant tumors.

Research Triangle Park
Falcon Therapeutics Inc.

Falcon Therapeutics is developing personalized neural stem cell therapies to treat cancers.

Durham
Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals develops a sodium thiosulfate formula for the prevention of ototoxicity from cisplatin in pediatric patients.

Research Triangle Park
FibroStatin Inc.

FibroStatin develops treatments for drug resistant cancer and organ fibrosis using its proprietary GPBP technology that has identified a novel and preferred pathway for inhibiting the cell epithelial-to-mesenchymal transition (EMT).

Raleigh
FLAG Therapeutics Inc.

FLAG Therapeutics develops cancer therapeutics using new classes of small molecules which have selective dual activity: antiangiogenesis and chemotherapeutic.

Raleigh
Foundation Medicine Inc.

Foundation Medicine develops and provides clinical assays that provide a comprehensive genomic profile to identify molecular alterations in a patient's cancer and match them with targeted therapies and clinical trials.

Morrisville
FusionBio Inc.

FusionBio develops novel treatments for immune-mediated diseases, including cancer and autoimmunity.

Chapel Hill
G1 Therapeutics Inc.

G1 Therapeutics discovers and develops small-molecule therapies to address significant unmet needs in oncology.

Research Triangle Park
GBM Pharma Inc.

GBM Pharma develops drugs for the treatment of glioblastoma multiforme.

Durham
GEM Tox Labs

GEM Tox Labs conducts research focused on cancer biotechnology, food safety and toxicology, with a special emphasis on cancer biomarker discovery and validation.

Greenville
GeneCentric Therapeutics Inc.

GeneCentric Diagnostics develops molecular diagnostic assays to enable oncologists and their patients to make informed, individualized treatment decisions.

Research Triangle Park
Genencine Therapeutics LLC

Genencine Therapeutics develops mRNA vaccines for the prevention and treatment of cancer, viral diseases and autoimmune diseases, as well as mRNA therapeutic drugs for genetic diseases.

Durham
Genetron Health Technologies Inc.

Genetron Health Technologies provides mutation detection assays using its liquid biopsy platform, as well as various genetic assays to support both clinical and basic research. Genetron also offers custom assay development.

Research Triangle Park
Grid Therapeutics LLC

Grid Therapeutics is developing cancer therapeutics that utilize a unique platform that develops human-derived antibodies for the treatment of multiple cancer types.

Durham
GSK

GSK develops and manufactures vaccines, medicines and consumer healthcare products, with a focus on science related to the immune system, use of genetics and advanced technologies.

Research Triangle Park
Heat Biologics Inc.

Heat Biologics develops combination therapies for the treatment of cancer. Heat Biologics is focused on T cell-stimulating therapeutic platform technologies used in combination with checkpoint inhibitors.

Durham
Immunolight LLC

Immunolight develops energy modulating technology to activate immunotherapeutics for the treatment of cancer.

Oak Island
Immunotherapy Technologies LLC

Immunotherapy Technologies provides consulting services for immunotherapeutic program development and strategic analysis, with a focus on preclinical-to-clinical transition in oncology and viral vaccines.

Cary
IMMvention Therapeutix Inc.

IMMvention Therapeutix develops a platform technology that modulates innate immunity to treat unmet medical needs in cancer, autoimmune/inflammatory and infectious diseases.

Durham
Inanovate Inc.

Inanovate has developed a patented blood analysis system (the Bio-ID) for diagnostic tests. The first application of the Bio-ID is a new blood test to detect breast cancer recurrence at a stage when it may still be cured.

Raleigh
Inivata Inc.

Inivata develops a noninvasive liquid biopsy diagnostic using the precision of circulating tumor DNA (ctDNA) analysis for improving cancer detection and assessing individual response to treatment.

Research Triangle Park
Innocrin Pharmaceuticals Inc.

Innocrin discovers and develops a novel small-molecule CYP17 lyase inhibitor that can be taken orally to treat castration-resistant prostate cancer.

Durham
ISTARI Oncology Inc.

ISTARI Oncology is developing immunotherapies for cancer treatment.

Durham
Kaio Therapy LLC

KAIO Therapy develops an immunotherapy technology to treat solid tumors.

Raleigh
Lucerno Dynamics LLC

Lucerno Dynamics is commercializing a noninvasive device for quality assurance and control in nuclear medicine imaging. Future applications of the technology include immunotherapy and chemotherapy assessment.

Cary
MAA Laboratories Inc.

MAA Laboratories is reformulating and commercializing existing proprietary anti-cancer small molecules, with the purpose of enhancing therapeutic efficiency for targeted drug delivery and mitigating undesirable effects of currently approved drugs.

Durham
Madera Therapeutics LLC

Madera Therapeutics is developing small molecule anti-cancer agents that function via an initial disruption of mitochondrial function ultimately leading to an immune response against the cancer.

Cary
MDxHealth Inc.

MDxHealth develops epigenetic technologies to personalize the diagnosis and treatment of cancer.

Hillsborough
MedKoo Biosciences Inc.

MedKoo supplies anticancer small molecule chemical reagents and kinase inhibitor for oncology research. MedKoo also offers drug discovery research services to the pharmaceutical industry, medical research organizations and academic institutions.

Morrisville
Meryx Inc.

Meryx is developing small-molecule, orally-bioavailable RTK inhibitors that inhibit growth and initiate anti-tumor immunity in hematologic and solid malignancies.

Chapel Hill
Metabolon Inc.

Metabolon is advancing the science of metabolomics for the clinic and life sciences research. Its technology and data are used for biomarker discovery, diagnostic test development, and genomics and population health initiatives.

Morrisville
Midatech Pharma US Inc.

Midatech Pharma US develops and commercializes oncology treatments and supportive care.

Raleigh
Mycosynthetix Inc.

Mycosynthetix manages a large collection of fungal isolates and discovers novel fungal metabolites for human and animal health and compounds for agricultural applications.

Hillsborough
NovaTarg Inc.

NovaTarg discovers and develops new medicines to treat metabolic diseases and cancer.

Research Triangle Park
OliVentures Inc.

OliVentures is developing olive oil polyphenol and omega-3 fatty acid supplements and products to support cardiovascular, breast and joint health.

Raleigh
Omicsoft Corp.

Omicsoft designs software for biomarker data management, visualization and analysis.

Cary
OncoTAb Inc.

OncoTAb develops and commercializes diagnostic blood tests designed to detect breast cancer and develops an immunotherapy for the treatment of pancreatic cancer.

Charlotte
OncoTrap Inc.

OncoTrap is developing a nucleic acid delivery platform for accommodating nucleic acid-based therapeutics, designed to deliver therapeutic genes to tumor sites.

Chapel Hill
Panacise Bio Inc.

Panacise Bio researches cell signaling pathways and develops CAR-T applications using molecular evolution techniques associated with targeting ligands and mRNA display technology.

Chapel Hill
Pathfinder Pharmaceuticals Inc.

Pathfinder Pharmaceuticals specializes in early stage drug discovery, with a focus on cancer therapy.

Durham
Phenogen Sciences Inc.

Phenogen Sciences provides predictive testing and risk assessment tools that help physicians proactively manage patient health.

Charlotte
PhosphoGam Inc.

PhosphoGam is developing allogeneic cell immunotherapies using gamma/delta T-cells to treat a variety of cancers.

Durham
Pique Therapeutics Inc.

Pique Therapeutics develops therapeutic vaccines for the treatment of cancer.

Durham
Precision BioSciences Inc.

Precision BioSciences utilizes a proprietary genome editing method called ARCUS to treat cancers and genetic diseases, and enable the development of safer, more productive food sources.

Durham
Preclinical Pathfinder Systems

Preclinical Pathfinder is a CRO providing preclinical study design and execution partnering with Duke and other universities. Expertise includes animal imaging, surgical models, phamacokinetics (PK), Phase I/translation and advanced model development.

Durham
RedHill Biopharma Inc.

RedHill Biopharma develops and commercializes orally-administered, small-molecule drugs for the treatment of gastrointestinal and inflammatory diseases, including cancer. Its Raleigh site is the company's U.S. commercial headquarters.

Raleigh
Reveris Therapeutics LLC

Reveris Therapeutics develops novel therapeutics for triple negative breast cancer (TNBC).

Chapel Hill
Roivant Sciences Inc.

Roivant Sciences acquires drug candidates or partners with the biopharma industry to complete the clinical development of shelved product candidates. Therapeutic areas include neurology, dermatology, hepatology, oncology, endocrinology and rare disease.

Durham
RTP Genomics LLC

RTP Genomics uses next-generation DNA sequencing and proprietary algorithms to count mutations in leukemic cells.

Chapel Hill
Salzburg Therapeutics Inc.

Salzburg Therapeutics is developing systems that deliver activated forms of anticancer drugs, nucleic acid drugs and nanoparticles directly to cancer cells.

Yadkinville
Sentinel Biomedical Inc.

Sentinel Biomedical develops and offers molecular diagnostics for the detection and monitoring of canine cancers. Sentinel also offers CRO services in the areas of molecular biology and genomics.

Raleigh
Shattuck Labs Inc.

Shattuck Labs is a preclinical-stage immunotherapy company focused on utilizing its proprietary ARC (Agonist Redirected Checkpoint) technology to develop novel treatments for use in cancer, inflammation and orphan disease.

Research Triangle Park
SonaCare Medical

SonaCare Medical develops minimally-invasive ultrasound technologies that ablate targeted soft tissue for the treatment of cancer.

Charlotte
SpringWorks Therapeutics LLC

SpringWorks Therapeutics develops standalone and combination therapies with a focus on rare diseases and oncology, including plexiform neurofibroma, desmoid tumors, RAS/RAF mutant solid tumors and CNS disorders. Its initial portfolio is from Pfizer.

Durham
Symberix Inc.

Symberix is developing microbiome-targeted, small-molecule drugs to treat serious lower gastrointestinal (GI) diseases as well as mitigate the lower GI side effects associated with various cancer, pain and immunosuppressive therapies.

Durham
Synthon Pharmaceuticals Inc.

Synthon Pharmaceuticals develops and manufactures generics, as well as specialty pharmaceuticals and biosimilars in key therapeutic areas of oncology and multiple sclerosis. The Durham location is a regulatory office.

Durham
TCRCure Biopharma Corp.

TCRCure Biopharma discovers and develops novel therapeutic targets in the field of cancer immunotherapy.

Durham
TheraBionic Inc.

TheraBionic is developing treatment approaches for cancer based on the use of tumor-specific modulation frequencies, with an initial focus in hepatocellular carcinoma.

Winston-Salem
Triangle Research Solutions Inc.

Triangle Research Solutions provides clinical trial services such as project management, AE/SAE monitoring, CRF design, IVRS consultation, site recruitment, patient recruitment, and protocol consultation.

Hillsborough
United Therapeutics Corp.

United Therapeutics develops and commercializes products to treat cardiopulmonary diseases, infectious diseases and cancer.

Research Triangle Park
VivImmune LLC

VivImmune is developing a chitosan-based delivery system for the local, sustained delivery of recombinant cytokines therapeutics to treat cancers.

Cary
Worldwide Clinical Trials Inc.

Worldwide Clinical Trials provides phase one through phase four drug development services to the pharmaceutical and biotechnology industries.

Morrisville
Xenobiotic Detection Systems International Inc.

Xenobiotic Detection Systems offers patented bioassays to facilitate assessment of environmental and human health risks.

Durham

Pages